Navigation Links
Sirius Genomics Announces Issuance of U.S. Patent
Date:10/26/2010

Sirius Genomics Announces Issuance of U.S. Patent


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals Click to view news release full screen  

Sirius Genomics Announces Issuance of U.S. Patent

 

VANCOUVER, Oct. 26 /PRNewswire/ - Sirius Genomics, a developer of companion diagnostics, announced today that U.S. Patent # 7,820,376 entitled "Protein C Polymorphisms" has been issued by the United States Patent and Trademark Office. The patent relates to a novel use of a Single Nucleotide Polymorphism (SNP) located in the Protein C gene.

"The patent covers methods of predicting outcome or prognosis in sepsis, and other related conditions, by determining a subject's genotype at the SNP. This patent issuance further strengthens Sirius' patent portfolio and position as a developer of companion diagnostics," stated Dr. Jennifer Kaufman-Shaw, Vice President, Intellectual Property at Sirius Genomics.

"Sirius Genomics' steadily expanding patent estate stems from discoveries made from the Company's focused approach in the identification and validation of genetic markers linked to drug response. Our focus is on improving outcomes for patients treated with various classes of drugs used in the acute care setting," stated Chris Wagner, President and CEO of Sirius Genomics.

Sirius' intellectual property portfolio includes patent families related to several therapies available and under development for sepsis and other acute conditions.  About Sirius Genomics: www.siriusgenomics.com
Sirius Genomics develops companion diagnostics (CDx) that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection. Learn more at href="http://www.siriusgenomics.com/">www.siriusgenomics.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.



'/>"/>
SOURCE Sirius Genomics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Sirius Genomics to Present at Invest Northwest Conference
3. Sirius Genomics Announces 2009 Board of Directors
4. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
5. Sirius Genomics Announces Change in Leadership
6. Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010
7. Industry Leaders from Blue Coat, Oracle, Polycom, Siemens and Taleo Headline SiriusDecisions Sales and Marketing Summit 2010
8. Sirius Genomics Announces Appointment of Senior Director of Business Development
9. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... and LONDON , May 23, 2016 ... Could See Frontage Boost Efficiency by 40% - Frontage ... - Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical ... with labs in the United States and ... to be deployed across its laboratory facilities. In addition to ...
(Date:5/23/2016)... ... 23, 2016 , ... Foresight Institute , a leading ... for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, named ... for experiment and the other for theory in nanotechnology. Prof. Markus J. Buehler, ...
(Date:5/20/2016)... CA (PRWEB) , ... May 20, 2016 , ... The ... 10 of its most experienced veterinary clients have treated over 100 of their own ... edge technology to provide the highest level of care for their patients. , ...
(Date:5/20/2016)... NC (PRWEB) , ... May 20, 2016 , ... Korean ... suggesting that it may offer a new way to treat the disease. Surviving Mesothelioma ... it now. , Scientists from several Korean institutions based their mesothelioma study on ...
Breaking Biology Technology:
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):